Market access without tears
This article was originally published in The Gray Sheet
Executive SummaryAMO vows to enter the $450 mil. artificial tears/dry eye care market in July 2005, following the expiration of a no-compete clause with former parent company Allergan. At the First Albany Capital analyst conference Dec. 7, Mazzo says AMO is ready to produce the solution using the same formulators as the firm uses for contact lens lubricants and solutions, but, failing that, "I will go out and acquire a technology"...
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.